Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

Minimally invasive glaucoma surgeries, like the iStent inject and Xen Gel Stent, are crucial for preventing disease progression. Technological innovations, including AI-driven diagnostics and ...

to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject ...

With over 20 years of experience, he has pioneered minimally invasive glaucoma surgeries (MIGS), including Trabectome, iStent and canaloplasty, transforming patient care. His research also focuses ...

Key products include the iStent and iStent inject W micro-bypass stents for treating open-angle glaucoma and the iDose TR, an intracameral implant that delivers glaucoma medication for up to three ...

GKOS is well-positioned to capitalize on the growing need for interventional glaucoma therapies and minimally invasive procedures. Key products such as iDose TR, iStent Infinite, and Epioxa are ...

On its third-quarter earnings call, Glaukos highlighted the increasing adoption of iStent Infinite for glaucoma patients, particularly those unresponsive to other treatments. This growth has been ...